Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

From her Oscar-winning turn as Queen Elizabeth I in Shakespeare in Love to her famously gender-swapped role as "M" in the ...

Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...

Macular degeneration is a leading cause of vision loss for people over 50, but there are ways to help protect your eyesight.

Collaboration between TLI and AMDF underscores a shared commitment to making a meaningful difference in the lives of those affected by AMD. Together, TLI and AMDF are dedicated to advancing awareness, ...

Long-term stabilizing of retinal exudation and fluid accumulation contributes to brolucizumab’s efficacy in managing wet age-related macular degeneration (AMD). Visual prognosis could be improved when ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...